SG10202106190RA - Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function - Google Patents
Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive functionInfo
- Publication number
- SG10202106190RA SG10202106190RA SG10202106190RA SG10202106190RA SG10202106190RA SG 10202106190R A SG10202106190R A SG 10202106190RA SG 10202106190R A SG10202106190R A SG 10202106190RA SG 10202106190R A SG10202106190R A SG 10202106190RA SG 10202106190R A SG10202106190R A SG 10202106190RA
- Authority
- SG
- Singapore
- Prior art keywords
- leucine
- acetyl
- pharmaceutically acceptable
- acceptable salt
- cognitive function
- Prior art date
Links
- WXNXCEHXYPACJF-ZETCQYMHSA-N N-acetyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-ZETCQYMHSA-N 0.000 title 1
- 229960000669 acetylleucine Drugs 0.000 title 1
- 230000003920 cognitive function Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201606834 | 2016-04-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10202106190RA true SG10202106190RA (en) | 2021-07-29 |
Family
ID=58633040
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202106190RA SG10202106190RA (en) | 2016-04-19 | 2017-04-19 | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
SG11201809031XA SG11201809031XA (en) | 2016-04-19 | 2017-04-19 | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201809031XA SG11201809031XA (en) | 2016-04-19 | 2017-04-19 | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
Country Status (14)
Country | Link |
---|---|
US (3) | US10905670B2 (es) |
EP (1) | EP3445351A1 (es) |
JP (2) | JP7387264B2 (es) |
KR (4) | KR102413754B1 (es) |
CN (1) | CN109069463B (es) |
AU (2) | AU2017252507B2 (es) |
BR (1) | BR112018071547A2 (es) |
CA (1) | CA3021155A1 (es) |
IL (3) | IL293266B2 (es) |
MX (2) | MX2018012739A (es) |
RU (2) | RU2745912C2 (es) |
SG (2) | SG10202106190RA (es) |
WO (1) | WO2017182802A1 (es) |
ZA (1) | ZA201806849B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10905670B2 (en) * | 2016-04-19 | 2021-02-02 | Intrabio Ltd. | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
GB201709459D0 (en) | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
MX2021006559A (es) * | 2018-12-06 | 2021-08-16 | Intrabio Ltd | Analogos deuterados de acetil-leucina. |
BR112021017203A2 (pt) * | 2019-03-02 | 2021-12-14 | Intrabio Ltd | Leucina, acetil leucina e análogos relacionados para o tratamento de doenças |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060063827A1 (en) * | 2004-09-23 | 2006-03-23 | Yu Ruey J | Systemic administration of therapeutic amino acids and N-acetylamino acids |
US20070190070A1 (en) * | 2004-09-03 | 2007-08-16 | Zeldis Jerome B | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
FR2905600B1 (fr) * | 2006-09-13 | 2010-01-15 | Pf Medicament | Traitement des vertiges par l'acetyl-l-leucine. |
US20120196257A1 (en) * | 2009-08-27 | 2012-08-02 | Joe Verghese | Cognitive function training to improve motor ability |
TN2010000251A1 (fr) * | 2010-06-03 | 2011-11-11 | Rekik Raouf | N-acetyl-dl-leucine medicament neuro et retino protecteur |
WO2012060844A1 (en) * | 2010-11-05 | 2012-05-10 | Biotie Therapies, Inc | A2a antagonists as cognition and motor function enhancers |
US10905670B2 (en) * | 2016-04-19 | 2021-02-02 | Intrabio Ltd. | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
EP3697406A1 (en) * | 2017-10-18 | 2020-08-26 | IntraBio Ltd | Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders |
-
2017
- 2017-04-19 US US16/093,780 patent/US10905670B2/en active Active
- 2017-04-19 KR KR1020227008412A patent/KR102413754B1/ko active IP Right Grant
- 2017-04-19 RU RU2018140131A patent/RU2745912C2/ru active
- 2017-04-19 SG SG10202106190RA patent/SG10202106190RA/en unknown
- 2017-04-19 WO PCT/GB2017/051090 patent/WO2017182802A1/en active Application Filing
- 2017-04-19 RU RU2021107001A patent/RU2021107001A/ru unknown
- 2017-04-19 IL IL293266A patent/IL293266B2/en unknown
- 2017-04-19 KR KR1020187032983A patent/KR20180134398A/ko not_active IP Right Cessation
- 2017-04-19 AU AU2017252507A patent/AU2017252507B2/en active Active
- 2017-04-19 MX MX2018012739A patent/MX2018012739A/es unknown
- 2017-04-19 CN CN201780029480.6A patent/CN109069463B/zh active Active
- 2017-04-19 KR KR1020247003393A patent/KR20240018683A/ko active Application Filing
- 2017-04-19 IL IL310508A patent/IL310508A/en unknown
- 2017-04-19 JP JP2018555644A patent/JP7387264B2/ja active Active
- 2017-04-19 KR KR1020227021015A patent/KR102632670B1/ko active IP Right Grant
- 2017-04-19 CA CA3021155A patent/CA3021155A1/en active Pending
- 2017-04-19 SG SG11201809031XA patent/SG11201809031XA/en unknown
- 2017-04-19 EP EP17719692.0A patent/EP3445351A1/en active Pending
- 2017-04-19 IL IL262379A patent/IL262379B/en unknown
- 2017-04-19 BR BR112018071547-6A patent/BR112018071547A2/pt active Search and Examination
-
2018
- 2018-10-15 ZA ZA2018/06849A patent/ZA201806849B/en unknown
- 2018-10-18 MX MX2021014844A patent/MX2021014844A/es unknown
-
2020
- 2020-12-22 US US17/247,757 patent/US11998518B2/en active Active
-
2021
- 2021-11-12 JP JP2021185130A patent/JP7506046B2/ja active Active
-
2022
- 2022-10-17 AU AU2022256077A patent/AU2022256077A1/en active Pending
-
2023
- 2023-07-10 US US18/349,221 patent/US20230346732A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL262107B (en) | Overlapping bangs | |
PL3874813T3 (pl) | Procedura mobilności | |
HUE049523T2 (hu) | Peszticidként hatásos szemikarbazon- és tioszemikarbazon-származékok | |
IL262379A (en) | Acetyl-leucine or its acceptable pharmacy salt for improved mobility and cognitive function | |
HUE048993T2 (hu) | Ágy csökkent mobilitással rendelkezõ személyek számára | |
IL272385A (en) | Drug compound and methods of preparation | |
GB201617064D0 (en) | Compounds and their therapeutic use | |
HUE060805T2 (hu) | Piridinamin-piridon és pirimidinamin-piridon vegyületek | |
IL270011B (en) | Medicinal compounds and methods | |
ZA201806247B (en) | Beta-caseins and cognitive function | |
IL267937A (en) | Amide compounds and their use | |
IL265269B (en) | New compounds and their medicinal uses | |
GB201616370D0 (en) | Wireless handover system | |
GB201700404D0 (en) | Compounds and composistions | |
HUE057818T2 (hu) | Azaindolilpiridon és diazaindolilpiridon vegyületek | |
EP3409662A4 (en) | NOVEL CONNECTION AND PHARMACEUTICALLY COMPATIBLE SALT OF WHICH | |
GB201617063D0 (en) | Condoms | |
GB2539264B (en) | Mobility aid | |
IL265617B (en) | 1-phenylpropanone compounds and their use | |
GB201720115D0 (en) | Mobility aid | |
PT3630997T (pt) | Monitorização terapêutica de fármacos | |
GB201720943D0 (en) | New processes and compounds | |
GB201702051D0 (en) | New Pharmaceutical use | |
GB201700872D0 (en) | A bed mobility aid | |
GB201616767D0 (en) | New pharmaceutical use |